Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of Organ Preservation Strategy by Adjuvant Chemoradiotherapy after Non-Curative Endoscopic Resection for Superficial SCC: A Multicenter Western Study.
Berger A, Perrod G, Pioche M, Barret M, Cesbron-Métivier E, Lépilliez V, Hupé M, Perez-Cuadrado-Robles E, Cholet F, Daubigny A, Texier C, Ali EA, Chabrun E, Jacques J, Wallenhorst T, Chevaux JB, Schaefer M, Cellier C, Rahmi G. Berger A, et al. Among authors: hupe m. Cancers (Basel). 2023 Jan 18;15(3):590. doi: 10.3390/cancers15030590. Cancers (Basel). 2023. PMID: 36765546 Free PMC article.
Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study.
Hupé M, Rivière P, Nancey S, Roblin X, Altwegg R, Filippi J, Fumery M, Bouguen G, Peyrin-Biroulet L, Bourreille A, Caillo L, Simon M, Goutorbe F, Laharie D. Hupé M, et al. Aliment Pharmacol Ther. 2020 May;51(9):852-860. doi: 10.1111/apt.15680. Epub 2020 Mar 22. Aliment Pharmacol Ther. 2020. PMID: 32201971
Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter study.
Hupé M, Streichenberger A, Wils P, Arab N, Serrero M, Amiot A, Bozon A, Vuitton L, Fumery M, Altwegg R, Nachury M, Hébuterne X, Yzet C, Coban D, Dodel M, Bazoge M, Pereira B, Buisson A. Hupé M, et al. Dig Liver Dis. 2024 Jan 27:S1590-8658(24)00200-7. doi: 10.1016/j.dld.2024.01.181. Online ahead of print. Dig Liver Dis. 2024. PMID: 38281870
Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn's Disease: A Retrospective Study From 2 Referral Centers.
Rivière P, Kanters C, Pellet G, Ni A, Hupé M, Aboulhamid N, Poullenot F, Bitton A, Zerbib F, Lakatos PL, Afif W, Laharie D, Bessissow T. Rivière P, et al. Among authors: hupe m. Inflamm Bowel Dis. 2023 Jun 1;29(6):923-931. doi: 10.1093/ibd/izac167. Inflamm Bowel Dis. 2023. PMID: 35917111
Impact of COVID-19 crisis on medical care of patients with metastasized uro-oncologic disease under systemic cancer therapy: a multicenter study in German university hospitals.
Struck JP, Schnoor M, Schulze A, Hupe MC, Ozimek T, Oppolzer IA, Schnabel MJ, Burger M, Darr C, Gruenwald V, Hadaschik B, Weinke M, Kuebler H, Klockenbusch JC, Grabbert MT, Gratzke C, Kramer MW, Katalinic A, Merseburger AS. Struck JP, et al. Among authors: hupe mc. World J Urol. 2022 Feb;40(2):409-418. doi: 10.1007/s00345-021-03868-2. Epub 2021 Nov 30. World J Urol. 2022. PMID: 34850270 Free PMC article.
Discrepancy between German S3 Guideline Recommendations and Daily Urologic Practice in the Management of Nonmuscle Invasive Bladder Cancer: Results of a Binational Survey.
Struck JP, Hennig MJP, Hupe MC, Moharam N, Paffenholz P, Nestler T, Frank T, Worst TS, Grabbert M, Pohlmann PF, Dogan S, Hofbauer SL, Kalogirou C, Mattigk A, Brandt MP, Krabbe LM, Reis H, Dressler FF, Kramer MW, Salem J. Struck JP, et al. Among authors: hupe mc. Urol Int. 2023;107(1):35-45. doi: 10.1159/000518166. Epub 2021 Aug 31. Urol Int. 2023. PMID: 34515257
Analysis of tripartite motif (TRIM) family gene expression in prostate cancer bone metastases.
Offermann A, Kang D, Watermann C, Weingart A, Hupe MC, Saraji A, Stegmann-Frehse J, Kruper R, Schüle R, Pantel K, Taubert H, Duensing S, Culig Z, Aigner A, Klapper W, Jonigk D, Philipp Kühnel M, Merseburger AS, Kirfel J, Sailer V, Perner S. Offermann A, et al. Among authors: hupe mc. Carcinogenesis. 2021 Dec 31;42(12):1475-1484. doi: 10.1093/carcin/bgab083. Carcinogenesis. 2021. PMID: 34487169
CDK19 as a diagnostic marker for high-grade prostatic intraepithelial neoplasia.
Offermann A, Joerg V, Hupe MC, Becker F, Müller M, Brägelmann J, Kirfel J, Merseburger AS, Sailer V, Tharun L, Perner S. Offermann A, et al. Among authors: hupe mc. Hum Pathol. 2021 Nov;117:60-67. doi: 10.1016/j.humpath.2021.07.006. Epub 2021 Jul 24. Hum Pathol. 2021. PMID: 34314763
[Diagnostic markers in urology].
Hupe MC, Hempel MC, Rodler S, Frantzi M, Mischak H, Merseburger AS, Stief CG, Chaloupka M. Hupe MC, et al. Urologe A. 2021 Oct;60(10):1323-1330. doi: 10.1007/s00120-021-01568-8. Urologe A. 2021. PMID: 34156515 Review. German.
107 results